Left ventricular remodeling in patients with chronic renal failure on outpatient hemodialysis


Cite item

Full Text

Abstract

Aim. To study left ventricular remodeling (LVR) in patients with end-stage renal disease (ESRD) treated by hemodialysis (HD).
Material and methods. A total of 122 patients with ESRD were examined: 21 patients with predialysis ESRD (group 1), 37 patients treated by HD for 4 hours thrice a week (group 2), 64 patients treated by HD for 5 hours thrice a week (group 3). All the patients have undergone echocardiography. Blood serum hemoglobin, urea, creatinine, albumin, calcium, phosphates, PTH were measured. URR and Kt/V were calculated in patients of group 2 and 3.
Results. LVM and ILVM were significantly higher in patients of group 2, excentric geometry predominated (63.2%).
Conclusion. Prolongation of HD procedure from 4 to 5 hours thrice a week positively influences left ventricular remodeling and increases the survival of ESRD patients treated by HD.

References

  1. Moeller S., Gioberge S., Brown G. ESRD patients in 2001: global overview of patients, treatment modalities & developing trends. Nephrol. Dial. Transplant 2002; 17: 2071-2076.
  2. Бикбов Б. Т., Томилина Н. А. О состоянии заместительной почечной терапии больных с хронической почечной недостаточностью в Российской Федерации в 2001 г. Нефрол. и диализ 2004; 1:4-42.
  3. Collins A. J., Hao W., Xia H. et al. Mortality risks of peritoneal & hemodialysis. Am. J. Kidney Dis. 1999; 34: 1065-1074.
  4. Innes A., Charra B., Burden R. P. et al. The effect of long, slow hemodialysis on patient survival. Nephrol. Dial. Transplant. 1999; 14: 919-922.
  5. Shinzato T., Nakai S., Akiba T. et al. Survival in long - hemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol. Dial. Transplant. 1997; 12: 884-888.
  6. Raj D. S. C., Charra B., Pierratos A. et al. In search of ideal hemodialysis: is prolonged frequent dialysis the answer? Am. J. Kidney Dis. 1999; 34: 597-610.
  7. Laurent G., Charra B. The results of an 8 h thrice a week hemodialysis achedule. Nephrol. Dial. Transplant. 1998; 13 (suppl. 6): 125-131.
  8. Dijk P. C. W. van, Jager K. J., Charro F. de et al. Renal replacement therapy in Europe: the results of collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol. Dial. Transpnant. 2001; 16: 1120-1129.
  9. Levey A. S., Beto J. A., Coronado B. E. et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am. J. Kidney Dis. 1998; 32: 853-906.
  10. Беленков Ю. Н., Мареев В. Ю. Сердечно-сосудистый континуум. Сердеч.-недостат. 2002; 1:7-11.
  11. Мухин Н. А., Моисеев В. С. Кардио-ренальные соотношения и риск сердечно-сосудистых заболеваний. Вестн. РАМН 2003; 11: 50-55.
  12. Мухин Н. А., Моисеев В. С., Кобалава Ж. Д. и др. Кардио-ренальные взаимоотношения: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. арх. 2004; 6: 39-46.
  13. De Lima J. J. G., Vieira M. L. C., Abensur H. et al. Baseline blood pressure and other variables influencing survival on hemodialysis of patients without overt cardiovascular disease. Nephrol. Dial. Transplant. 2001; 16: 793-797.
  14. Foley R. N., Parfrey P. S., Harnett J. D. et al. Clinical and echocardiographic disease in patients starting end - stage renal disease therapy. Kidney Int. 1995; 47: 186-192.
  15. Zoccali C., Benedetto S. M., Mallamaci F. et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J. Am. Soc. Nephrol. 2001; 12: 2768-2774.
  16. Devereux R. B., Alonso D. R., Lutas E. M. et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986; 57: 450-458.
  17. Профилактика, диагностика и лечение артериальной гипертензии: Российские рекомендации ВНОК. М.; 2004.
  18. Волгина Г. В. Клиническая эпидемиология кардиоваскулярных нарушений при хронической почечной недостаточности. Нефрол. и диализ 2000; 1-2; 25-32.
  19. Greaves S. C., Gamble G. D., Collins J. E. et al, Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am. J. Kidney Dis. 1994; 24 (5): 768-776.
  20. Straumann E., Bartel O., Meyer B. et al. Symmetric and asymmetric left ventricular hypertrophy in patients with end - stage renal failure on long - term hemodialysis. Clin. Cardiol. 1998; 21 (9): 672-678.
  21. Levin A., Singer J., Thompson C. R., Lewis M. Pravalent left ventricular hypertrophy in the predialysis population: Identufying the opportunities for intervention. Am. J. Kidney Dis. 1996; 27: 347-354.
  22. London G. M., Fabiani F. Left ventricular dysfunction in end - stage renal disease: Echocardiographic insights. In: Parfrey P. S., Harnett J. D. eds Cardiac dysfunction in chronic uremia. Boston: Kluwer; 1992. 117-138.
  23. Thuraisingham R. C., Tucker B., Lipkin G. W. et al. Left ventricular hypertrophy in early failure. Nephrol. Dial. Transplant. 1994; 7: 859-860.
  24. Бадаева С. В., Томилина Н. А., Бикбов Б. Т. и др. Структурно-функциональные изменения миокарда при прогрессировании ХПН. Нефрол. и диализ 2006; 3: 232-239.
  25. Волгина Г. В. Паратиреоидный гормон - универсальный уремический токсин. Нефрол. и диализ 2000; 1-2: 32-38.
  26. Cannata-Andia J. B., Rodriges-Garcia M. Hyperphospatemia as cardiovascular risk - how to manage the problem. Nephrol. Dial. Transplant. 2002; suppl. 11: 16-19.
  27. Block G. A., Hulbert-Shearon T. E., Levin N. W., Port F. K. Association of serum phosphorus and calcium-phosphate product with mortality risk in chronic hemodialysis patients: a mational study. Am. J. Kidney Dis. 1998; 31: 607-617.
  28. Кутырина И. М., Руденко Т. Е., Дзитоева М. Ю. Ремоделирование сосудов при хронической почечной недостаточности. Клин. мед. 2005; 2: 16-21.
  29. Ильин А. П. Актуальные синдромы, отягощающие течение хронической почечной недостаточности у больных, находящихся на лечении программным гемодиализом: диагностика, лечение, профилактика, прогноз. М.: Корпорация технологий продвижения; 2002.
  30. Pifer T. B., McCullough K. P., Port F. K. et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int. 2002; 62: 2238-2245.
  31. Клиническое практическое руководство по адекватности гемодиализа: Пер. с англ. Тверь: Губернская медицина; 1999.
  32. Lima De J. D., Abensur H., Krieger E. M., Pileggi F. Arterial blood pressure and left ventricular hypertrophy in hemodialysis patients. J. Hypertens, 1996; 14: 1019-1024.
  33. Ganau A., Devereux R. B., Roman H. J. et al. Patterns of lift ventricular hypertrophy and geometric remodeling inessential hypertension. J. Am. Coll. Cardiol. 1992; 19: 1550-1558.
  34. Николс Э. Д. Сердце и система циркуляции. В кн.: Даугирдас Д. Т. (ред.). Руководство по диализу: Пер. с англ. Тверь: Триада; 2003.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies